Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts give Tarsus a consensus rating of Moderate Buy from nine firms with a one‑year average target price of $91.83, and recent notable calls include Oppenheimer raising its target to $105 and Lifesci Capital upgrading to strong‑buy.
• Company insiders have been net sellers — the CEO and general counsel sold shares on March 19, and insiders disposed of 79,391 shares worth about $5.43M over the past 90 days, leaving insiders with 8.97% ownership.
• TARS trades around $72.56 with a market cap of $3.09B and a 12‑month range of $38.51–$85.25; the company reported a slight EPS miss and negative earnings despite revenue beating estimates.

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, four have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $91.8333.

Several brokerages recently weighed in on TARS. Wall Street Zen raised shares of Tarsus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, April 4th. Oppenheimer boosted their target price on shares of Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the company an "outperform" rating in a research note on Wednesday, February 25th. The Goldman Sachs Group reissued a "neutral" rating and issued a $68.00 target price on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Lifesci Capital upgraded Tarsus Pharmaceuticals to a "strong-buy" rating in a report on Monday, March 16th. Finally, Zacks Research cut Tarsus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 25th.

Insider Buying and Selling

In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 4,231 shares of Tarsus Pharmaceuticals stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $67.00, for a total value of $283,477.00. Following the completion of the sale, the general counsel owned 63,959 shares in the company, valued at $4,285,253. The trade was a 6.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Bobak R. Azamian sold 11,964 shares of Tarsus Pharmaceuticals stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $801,588.00. Following the completion of the sale, the chief executive officer owned 33,421 shares of the company's stock, valued at $2,239,207. This trade represents a 26.36% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 79,391 shares of company stock worth $5,432,035 over the last ninety days. Insiders own 8.97% of the company's stock.

Institutional Trading of Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rockefeller Capital Management L.P. grew its holdings in Tarsus Pharmaceuticals by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company's stock valued at $105,000 after buying an additional 172 shares during the period. State of Wisconsin Investment Board grew its holdings in shares of Tarsus Pharmaceuticals by 1.1% during the 4th quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company's stock worth $2,613,000 after purchasing an additional 332 shares during the period. Federated Hermes Inc. grew its holdings in shares of Tarsus Pharmaceuticals by 0.6% during the 2nd quarter. Federated Hermes Inc. now owns 55,021 shares of the company's stock worth $2,229,000 after purchasing an additional 339 shares during the period. Valeo Financial Advisors LLC grew its holdings in shares of Tarsus Pharmaceuticals by 11.1% during the 4th quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company's stock worth $321,000 after purchasing an additional 392 shares during the period. Finally, Creative Planning grew its holdings in shares of Tarsus Pharmaceuticals by 3.3% during the 3rd quarter. Creative Planning now owns 12,367 shares of the company's stock worth $735,000 after purchasing an additional 393 shares during the period. Hedge funds and other institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock opened at $72.56 on Monday. The firm has a 50-day moving average price of $68.65 and a 200 day moving average price of $71.93. Tarsus Pharmaceuticals has a twelve month low of $38.51 and a twelve month high of $85.25. The company has a market capitalization of $3.09 billion, a price-to-earnings ratio of -44.79 and a beta of 0.63. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The firm had revenue of $151.67 million during the quarter, compared to analyst estimates of $144.56 million. Research analysts forecast that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.